Literature DB >> 24853758

Genetic and chemical analyses reveal that trypanothione synthetase but not glutathionylspermidine synthetase is essential for Leishmania infantum.

André F Sousa1, Ana G Gomes-Alves1, Diego Benítez2, Marcelo A Comini2, Leopold Flohé3, Timo Jaeger4, Joana Passos1, Friedrich Stuhlmann5, Ana M Tomás6, Helena Castro7.   

Abstract

Trypanothione is a unique and essential redox metabolite of trypanosomatid parasites, the biosynthetic pathway of which is regarded as a promising target for antiparasitic drugs. Synthesis of trypanothione occurs by the consecutive conjugation of two glutathione molecules to spermidine. Both reaction steps are catalyzed by trypanothione synthetase (TRYS), a molecule known to be essential in Trypanosoma brucei. However, other trypanosomatids (including some Leishmania species and Trypanosoma cruzi) potentially express one additional enzyme, glutathionylspermidine synthetase (GSPS), capable of driving the first step of trypanothione synthesis yielding glutathionylspermidine. Because this monothiol can substitute for trypanothione in some reactions, the possibility existed that TRYS was redundant in parasites harboring GSPS. To clarify this issue, the functional relevance of both GSPS and TRYS was investigated in Leishmania infantum (Li). Employing a gene-targeting approach, we generated a gsps(-/-) knockout line, which was viable and capable of replicating in both life cycle stages of the parasite, thus demonstrating the superfluous role of LiGSPS. In contrast, elimination of both LiTRYS alleles was not possible unless parasites were previously complemented with an episomal copy of the gene. Retention of extrachromosomal LiTRYS in the trys(-/-)/+TRYS line after several passages in culture further supported the essentiality of this gene for survival of L. infantum (including its clinically relevant stage), hence ruling out the hypothesis of functional complementation by LiGSPS. Chemical targeting of LiTRYS with a drug-like compound was shown to also lead to parasite death. Overall, this study disqualifies GSPS as a target for drug development campaigns and, by genetic and chemical evidence, validates TRYS as a chemotherapeutic target in a parasite endowed with GSPS and, thus, probably along the entire trypanosomatid lineage.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Free radicals; Glutathionylspermidine; Leishmania; Target validation; Trypanosoma; Trypanothione

Mesh:

Substances:

Year:  2014        PMID: 24853758     DOI: 10.1016/j.freeradbiomed.2014.05.007

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  13 in total

1.  LiZIP3 is a cellular zinc transporter that mediates the tightly regulated import of zinc in Leishmania infantum parasites.

Authors:  Sandra Carvalho; Rosa Barreira da Silva; Ali Shawki; Helena Castro; Márcia Lamy; David Eide; Vítor Costa; Bryan Mackenzie; Ana M Tomás
Journal:  Mol Microbiol       Date:  2015-03-11       Impact factor: 3.501

2.  Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning.

Authors:  Lucas N Alberca; María L Sbaraglini; Darío Balcazar; Laura Fraccaroli; Carolina Carrillo; Andrea Medeiros; Diego Benitez; Marcelo Comini; Alan Talevi
Journal:  J Comput Aided Mol Des       Date:  2016-02-18       Impact factor: 3.686

3.  Calcium and magnesium ions modulate the oligomeric state and function of mitochondrial 2-Cys peroxiredoxins in Leishmania parasites.

Authors:  Mariana A B Morais; Priscila O Giuseppe; Tatiana A C B Souza; Helena Castro; Rodrigo V Honorato; Paulo S L Oliveira; Luis E S Netto; Ana M Tomas; Mario T Murakami
Journal:  J Biol Chem       Date:  2017-03-14       Impact factor: 5.157

4.  A Simple Bioluminescent Assay for the Screening of Cytotoxic Molecules Against the Intracellular Form of Leishmania infantum.

Authors:  Diego Benítez; Andrea Medeiros; Cristina Quiroga; Marcelo A Comini
Journal:  Methods Mol Biol       Date:  2022

5.  Trypanothione synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in Trypanosoma cruzi.

Authors:  Andrea C Mesías; Natalia Sasoni; Diego G Arias; Cecilia Pérez Brandán; Oliver C F Orban; Conrad Kunick; Carlos Robello; Marcelo A Comini; Nisha J Garg; M Paola Zago
Journal:  Free Radic Biol Med       Date:  2018-10-23       Impact factor: 7.376

6.  Mitochondrial peroxiredoxin functions as crucial chaperone reservoir in Leishmania infantum.

Authors:  Filipa Teixeira; Helena Castro; Tânia Cruz; Eric Tse; Philipp Koldewey; Daniel R Southworth; Ana M Tomás; Ursula Jakob
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

7.  Ensemble learning application to discover new trypanothione synthetase inhibitors.

Authors:  Juan I Alice; Carolina L Bellera; Diego Benítez; Marcelo A Comini; Pablo R Duchowicz; Alan Talevi
Journal:  Mol Divers       Date:  2021-07-15       Impact factor: 2.943

8.  A single-cysteine mutant and chimeras of essential Leishmania Erv can complement the loss of Erv1 but not of Mia40 in yeast.

Authors:  Sandra Specht; Linda Liedgens; Margarida Duarte; Alexandra Stiegler; Ulrike Wirth; Maike Eberhardt; Ana Tomás; Kai Hell; Marcel Deponte
Journal:  Redox Biol       Date:  2017-12-23       Impact factor: 11.799

9.  Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.

Authors:  Verónica Gómez Pérez; Raquel García-Hernandez; Victoriano Corpas-López; Ana M Tomás; Joaquina Martín-Sanchez; Santiago Castanys; Francisco Gamarro
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-06-04       Impact factor: 4.077

10.  Identification of Novel Chemical Scaffolds Inhibiting Trypanothione Synthetase from Pathogenic Trypanosomatids.

Authors:  Diego Benítez; Andrea Medeiros; Lucía Fiestas; Esteban A Panozzo-Zenere; Franziska Maiwald; Kyriakos C Prousis; Marina Roussaki; Theodora Calogeropoulou; Anastasia Detsi; Timo Jaeger; Jonas Šarlauskas; Lucíja Peterlin Mašič; Conrad Kunick; Guillermo R Labadie; Leopold Flohé; Marcelo A Comini
Journal:  PLoS Negl Trop Dis       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.